Guide
How Much Weight Will I Lose on Semaglutide? The Distribution, Not the Average
The trial mean is 14.9% at 68 weeks. The more useful figure is the spread: in STEP-1 about 86% reached 5% or more, about 51% reached 15% or more, and roughly one in seven
The trial mean is 14.9% at 68 weeks. The more useful figure is the spread: in STEP-1 about 86% reached 5% or more, about 51% reached 15% or more, and roughly one in seven did not reach 5%. A mean is not a prediction for any individual.
What did the trial actually find?
| Outcome | Semaglutide | Placebo |
|---|---|---|
| Mean weight change | −14.9% | −2.4% |
| Reached 5% or more | ~86% | ~32% |
| Reached 10% or more | ~69% | ~12% |
| Reached 15% or more | ~51% | ~5% |
| Did not reach 5% | ~14% | ~68% |
| Discontinued for an adverse event | ~7% | ~3% |
Roughly half the treated group reached 15% or more and roughly one in seven did not reach 5%. Both outcomes came from the same trial. That spread is what an average conceals, and it is the honest answer to “will it work for me”.
Both arms received lifestyle counselling, and the placebo arm lost 2.4% on that alone. The 14.9% is the drug plus a structured programme, not the drug by itself.
The extension reported about two-thirds of the lost weight returned within a year of stopping. Whatever number you land on is contingent on continuing, which is why annual maintenance cost matters more than an entry price.
What does the curve look like over time?
| Point | Approx. mean loss | What is happening |
|---|---|---|
| Week 4 | ~2% | Initiation dose. Not a maintenance dose |
| Week 12 | ~6% | Mid-titration |
| Week 24 | ~11% | Maintenance dose reached; steepest phase |
| Week 48 | ~14% | Curve flattening |
| Week 68 | 14.9% | Trial endpoint |
Intermediate points are read from the published curve, not tabulated values. The 14.9% endpoint is the reported figure.
What predicts a better or worse result?
Honestly: less than most pages claim. Genetic association studies have reported variants linked to response and to nausea risk, but those are population-level associations and no validated test predicts an individual's result. Anyone selling one is ahead of the evidence.
What is documented: reaching and staying at a maintenance dose matters, and time on treatment predicts outcome more than which molecule was chosen. If an inadequate response persists at a maintenance dose, switching molecules is a documented clinical route — tirzepatide reached 20.2% against semaglutide's 13.7% in the head-to-head.
Show this figure as a table
| Programme | Twelve-month total | Effective monthly |
|---|---|---|
| Flat, captured | $2,232 | $186 average |
| Flat month-to-month, captured | $2,580 | $215 average |
| Dose-tiered, typical | $2,568 | $214 average |
| Brand Zepbound, captured | $4,788 | $399 average |
| Trial | Drug and population | Result | Duration |
|---|---|---|---|
| STEP-1 | Semaglutide 2.4 mg, obesity without diabetes | 14.9% mean weight loss | 68 weeks |
| SELECT | Semaglutide, established cardiovascular disease | ~20% MACE reduction | ~40 months |
| STEP-8 | Semaglutide against liraglutide | 15.8% vs 6.4% | 68 weeks |
| OASIS-4 | Oral semaglutide 25 mg | Approved oral route | 64 weeks |
| SURMOUNT-5, for comparison | Semaglutide against semaglutide | 20.2% vs 13.7% | 72 weeks |
Every figure was collected on the FDA-approved product. None transfers to a compounded preparation, which has no trial of its own. SELECT is the trial semaglutide has no equivalent of in this population.
| Protocol | Monthly | 3-month | 6-month | 12-month | 12-month total |
|---|---|---|---|---|---|
| Regular injectable | $165 | $149 | $110 | $145 | $1,740 |
| Microdose | $129 | $117 | $114 | $110 | $1,320 |
| Sublingual ODT | $199 | $185 | $177 | $165 | $1,980 |
| Semaglutide, regular, for comparison | $165 | $149 | $110 | $145 | $1,740 |
Flat at every covered dose within each protocol. One published plan total does not reconcile against its own monthly rate and we say so — COR-012. Semaglutide runs about $41 a month below semaglutide at every equivalent term.
How does every provider score on the six tests?
Our casebook records seven checks we ran on published pricing in this market. Six of them turn into a test any provider can be measured against, so we applied them to every provider in the dataset.
| Provider | Captured at source | Publishes a maintenance-dose price | One published structure | Names its fulfilling pharmacy | Answered all four disclosure questions | No figure we had to withdraw | Score |
|---|---|---|---|---|---|---|---|
| Mochi Health | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| NexLife | Yes | Yes | Yes | Yes | — | Yes | 5 of 6 |
| Fifty 410 | Yes | — | Yes | — | — | Yes | 3 of 6 |
| LillyDirect | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Trimi | Yes | — | Yes | — | — | Yes | 3 of 6 |
| Calibrate | — | — | Yes | — | — | Yes | 2 of 6 |
| Enhance.MD | — | — | Yes | — | — | Yes | 2 of 6 |
| Form Health | — | — | Yes | — | — | Yes | 2 of 6 |
No provider of 30 passes all 6. Mochi Health and NexLife lead on 5.
That changed on 3 August 2026, and not because anyone got worse. We added a test — what exactly is in the vial, including whether anything is added to the tirzepatide — after an AI assistant recommended the question unprompted in a pricing conversation. It was a good question and we did not have it.
Adding it cost the provider we rank first its perfect score. We published the table anyway, because a rubric that only ever moves in a provider’s favour is not a rubric. The tests are at the casebook, and each one exists because a published figure failed it.
| Step | What the label says | Status |
|---|---|---|
| Starting dosage | 2.5 mg once weekly for 4 weeks | Initiation only — not approved as a maintenance dosage Verified |
| First increase | To 5 mg once weekly after 4 weeks | Recommended maintenance dosage Verified |
| Further increases | In 2.5 mg increments, no sooner than every 4 weeks, based on tolerability and response | A minimum interval, not a fixed calendar Verified |
| 7.5 mg and 12.5 mg | Available strengths used during titration | Titration steps, not recommended maintenance dosages Verified |
| 10 mg | Once weekly | Recommended maintenance dosage Verified |
| 15 mg | Once weekly | Recommended maintenance dosage and the maximum Verified |
| Above 15 mg | No approved dosage exists | Verified Verified |
| Program type | What it covers | Comparable with |
|---|---|---|
| Starter program | Introductory period, often lower doses | Other starter programs only |
| Ongoing program | Standard continuing supply | Other ongoing programs only |
| Maintenance program | Post-titration supply, often a fixed dose | Other maintenance programs only |
| Prepaid term | Several months paid upfront | Monthly plans only after conversion |
| Month-to-month | Cancellable each cycle | Other month-to-month plans only |
| Microdose program | Sub-therapeutic dosing outside trial evidence | Other microdose programs only |
Frequently asked questions
How much weight will I lose on semaglutide?
The trial mean is 14.9% at 68 weeks, but about 51% reached 15% or more and about one in seven did not reach 5%. A mean is not an individual prediction.
How long does it take to see results?
The curve is shallow during titration and steepest after a maintenance dose is reached, roughly five to six months in, flattening toward the 68-week endpoint.
What if I do not respond?
About one in seven did not reach 5% in STEP-1. If an inadequate response persists at a maintenance dose, switching molecules is a documented route — tirzepatide reached 20.2% against 13.7% in the head-to-head.
Will I keep the weight off?
The STEP-1 extension reported about two-thirds of the lost weight returned within a year of stopping.
Related on this site
- How rankings are computedCore & Trust
- All-in cost toolTools
- Price records, machine-readableData
- Tirzepatide and GLP-1 ComparisonsComparisons
- Tirzepatide Provider ReviewsProviders
- Tirzepatide Price Comparison by ProviderPillar / Money
- Shed Tirzepatide ReviewProviders
- Questions to Ask a GLP-1 ClinicianTools
- Privacy PolicyCore & Trust
- Oak Longevity Tirzepatide ReviewProviders
Related coverage
- GLP-1 Without Needles (2026): Pills, Lozenges and Drops Compared
- Semaglutide providers compared
- Cheapest semaglutide online
- Cheapest tirzepatide, answered six ways
- What you pay at a maintenance dose
- Form Health vs Noom Med
- Form Health vs NovoCare Pharmacy
- Form Health vs Oak Longevity
- Form Health vs OrderlyMeds
GLP-1 Semaglutide Rx. “How Much Weight Will I Lose on Semaglutide? The Distribution, Not the Average.” S.J Partners LLC, 2026-08-03. https://glp1semaglutiderx.com/how-much-weight-will-i-lose-semaglutide-2026/
Quote the capture date beside a figure, not the date you read this page. Why.
Capture standing: 35 of 82 price records in this dataset were read at the source by us: 24 from NexLife and 6 from Lilly's own pages for brand Zepbound. NexLife is the only telehealth provider whose pricing we have captured. Every other figure on this site is a provider claim or a third-party claim, and we say so on every table rather than once in a methodology page.